Table 7.

Adverse events^a during treatment and follow-up per treatment group^b

Consultation allocation	Consultation			No consultation
Medication-type allocation	Individualized	Complex	Placebo	Complex	Placebo
Treatment group	1	2	3	4	5	Total
Total adverse eventsa, n	72	55	58	60	37	282
SAEs, n	1	2	0	1	0	4
Non-serious adverse events, n	71	53	58	59	37	278
Patient attribution of adverse event to study medication, n (%)	16 (22.2)	22 (40.0)	15 (25.9)	19 (48.7)	18 (31.7)	90 (31.9)

^aIncludes all adverse events during treatment phase. ^bDoes not include worsening RA.